Matthew Herper covers medical innovation — both its promise and its perils. SAN FRANCISCO — At the end of a roundtable lunch with a group of reporters, Pfizer CEO Albert Bourla became impassioned. He ...

PostEra's machine learning technology is intended to accelerate the drug discovery process by designing novel molecular structures with optimised potency and drug-like properties. PostEra's approaches ...

Pfizer & Merck are the boring intentional reset w/flat growth expectations. Pfizer now offers high dividends, Merck offers ...

Investing.com -- Adaptive Biotechnologies Corp (NASDAQ:ADPT) stock rose 4.3% in Monday premarket trading following the announcement of two non-exclusive agreements with Pfizer Inc (NYSE:PFE) that ...

I reaffirm my Buy rating on Pfizer due to expected promising updates on danuglipron and strong capital efficiency metrics, despite the recent stock pullback. Pfizer's management is expected to ...

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including UnitedHealth Group, Pfizer and ...

Pfizer is strengthening its franchise in respiratory vaccines and treatments, Dr. Mikael Dolsten, the chief scientific officer, said on the Nov. 1 call. It’s racing against GSK and Moderna to be first ...

View post: 60-year-old gym chain announces 23 location closures in shocking move View post: Are the Top 10% of American Consumers Really Driving 50% of Spending? Economists Debate. Are the Top 10% of ...

For drugmaker Pfizer, a fortune amassed in the COVID pandemic is now paving the path to pharma nirvana: a weight loss pill worth billions. The company has reaped nearly $100 billion from selling COVID ...

In a move that might allow them to sell drugs directly to patients, some drugmakers are getting into the telehealth business. Some major pharmaceutical companies are getting into the telehealth ...

Vaccines to block COVID-19 that are in development by Moderna, Pfizer, AstraZeneca and others, and that are currently in Phase III clinical trials, may not do as well covering people of Black or Asian ...

SAN FRANCISCO, Dec. 7, 2020 /PRNewswire/ -- PostEra, a biotechnology company specializing in machine learning solutions for preclinical drug discovery, today announced a strategic partnership with ...